Treat and Train - A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis
Phase of Trial: Phase IV
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms Treat & Train
- Sponsors AbbVie
- 12 Sep 2018 Status changed from recruiting to discontinued due to low or no enrollment.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 Planned number of patients changed from 600 to 510.